Jazz, Celator receive US antitrust approval for merger
MLex Summay: Jazz Pharmaceuticals and Celator Pharmaceuticals have received antitrust clearance for their proposed merger, as the waiting period under the Hart-Scott-Rodino Act expired on June 24, according to a regulatory...To view the full article, register now.
Already a subscriber? Click here to view full article